Leptomeningeal metastasis is an uncommon but serious complication in patients with advanced cancers. Leptomeningeal metastasis is diagnosed in approximately 5% of the patients, most commonly among patients with cancers of breast and lung, melanoma, and gastrointestinal malignancies. Treatment goal is to improve survival and quality of the patients. Use of targeted therapies and immunotherapy has led to improved survival of patients with non-small cell lung cancer (NSCLC). In this article, we review emerging data on use of mutation-specific agents and immunotherapy in the treatment of leptomeningeal metastasis among patients with NSCLC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775022PMC
http://dx.doi.org/10.21147/j.issn.1000-9604.2017.06.08DOI Listing

Publication Analysis

Top Keywords

leptomeningeal metastasis
12
non-small cell
8
cell lung
8
lung cancer
8
patients
6
targeted therapy
4
leptomeningeal
4
therapy leptomeningeal
4
leptomeningeal metastases
4
metastases non-small
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!